Sanofi Q3 2020 business EPS growth of 8.8% at CER
Third quarter 2020 results were reviewed by management during a conference call with the financial community.
- Presentation
- Press release
- Q3 2020 income statements
- Q3 2020 net sales by GBU, franchise, geographic region and product
- R&D appendices
- Clinical trials appendices
- Download infographic
- Q3 2020 Memorandum for modelling purposes
- Access the recorded audio webcast
Webcast details
Q3 2020 Results from Sanofi